Education
About Us
Working with TipRanks
Follow Us
Know Labs (KNW)
:KNW
Top Page
Know Labs
(NYSE MKT:KNW)
Rating:28Underperform
Price Target:―
Know Labs (KNW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.37M
Dividend YieldN/A
Average Volume (3M)10.08M
Price to Earnings (P/E)―
Beta (1Y)3.06
Revenue GrowthN/A
EPS Growth47.57%
CountryUS
Employees12
SectorTechnology
Sector Strength87
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)-1.60
Shares Outstanding7,497,948
10 Day Avg. Volume1,140,354
30 Day Avg. Volume10,077,144
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-153.85
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Know Labs Business Overview & Revenue Model
Company DescriptionKnow Labs (KNWN) is a biotechnology company specializing in the development and commercialization of non-invasive medical diagnostic technology. The company's core product leverages its patented Bio-RFID™ technology, which uses radiofrequency spectroscopy to analyze molecular signatures in the human body. This technology is primarily applied to glucose monitoring, providing an alternative to traditional invasive blood glucose tests.
How the Company Makes MoneyKnow Labs makes money by developing and licensing its proprietary Bio-RFID™ technology. The company's revenue streams include technology licensing fees, partnerships with medical device manufacturers, and potential direct sales of its diagnostic devices. Significant partnerships with healthcare firms and medical technology companies contribute to its earnings by facilitating the integration of its technology into existing and new medical platforms. Additionally, Know Labs may generate revenue through collaborations for research and development, as well as through potential future regulatory approvals that could lead to broader market adoption.
Know Labs Earnings Call Summary
Earnings Call Date:Feb 14, 2025
(Q2-2024)
| % Change Since: 410.42%|
Next Earnings Date:May 20, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of promising technological advancements and clinical results, coupled with financial challenges and a need for further capital. The company is making significant strides in product development and intellectual property, but faces issues with cash reserves and shareholder equity.Q2-2024 Updates
Positive Updates
Gen 2 Device Development - KnowU
The KnowU, a wearable noninvasive continuous glucose monitoring device, was announced on February 27. It is significantly smaller, lighter, includes onboard computing power, and built-in machine learning capabilities.
Positive Clinical Trial Results
An internal trial with more than 30 participants showed a mean absolute relative difference (MARD) of 11.1%, indicating promising accuracy of the glucose monitoring technology.
Significant Intellectual Property Growth
Over 300 patents issued, pending, and in process, reflecting innovation in radio frequency spectroscopy technology.
Funding Agreement Secured
Entered into a funding agreement for an investment of up to $12 million with Lind Global Fund II LP to accelerate development.
Engagement with Diabetes Community
Participated in significant conferences like ATTD, where the KnowU was displayed, and received an emerging technology grant as an outstanding startup.
Reduction in Operating Loss
Operating loss decreased by 1.7% from $4.81 million in Q2 fiscal 2023 to $4.73 million in Q2 fiscal 2024.
Negative Updates
Negative Shareholder Equity
Shareholder equity for Q2 fiscal 2024 was a negative $1.75 million versus $3.74 million in fiscal '23 ending September 30, 2023.
Cash and Cash Equivalents Decrease
Cash and cash equivalents decreased to $4.71 million compared to $8.02 million at the end of September 30, 2023.
Increased SG&A Expenses
Selling, general and administrative expenses increased by 13.7% year-over-year, mainly due to key hires and legal expenses.
High Burn Rate and Need for Additional Financing
Net cash used in operations was $7.05 million for the first 6 months, indicating a need for further capital raising.
Company Guidance
During the Know Labs Q2 2024 earnings call, the company provided several updates and guidance on its progress across key work streams. The company highlighted the development of its Generation 1 and Generation 2 (KnowU) noninvasive continuous glucose monitoring devices, with the latter being smaller, lighter, and equipped with built-in machine learning capabilities. Clinical trials have been promising, with a mean absolute relative difference (MARD) of 11.1% achieved, and plans to improve this to 10% or less. Financially, Know Labs reported an operating loss of $4.73 million, a slight improvement from the previous year, and maintained a cash balance of $4.71 million as of March 31, 2024. The company has secured up to $12 million in funding to support its core work streams and plans to raise additional funds through equity offerings to address its negative shareholder equity of $1.75 million. Know Labs is also actively expanding its intellectual property portfolio, with over 300 patents issued or pending globally. The company is positioning itself to achieve FDA clearance and commercialize its innovative glucose monitoring technology while exploring international opportunities.Know Labs Financial Statement Overview
Summary
Know Labs presents a challenging financial picture with substantial losses, high leverage, and negative cash flows. The income statement reveals operational inefficiencies with negative margins. The balance sheet shows high leverage with negative equity, indicating financial instability. Cash flows are negative, showing liquidity issues and reliance on external funding.Income Statement
The company has experienced inconsistent revenue patterns over the years, with significant negative net income and gross profit in the TTM. The gross profit and net profit margins are negative, indicating operational inefficiencies. EBIT and EBITDA margins are similarly negative, suggesting a challenge in generating core earnings and cash flows from operations.10
Very Negative
Balance Sheet
The balance sheet shows high leverage with a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, suggesting the company is heavily reliant on debt financing. Return on equity is not calculable with negative equity, indicating poor returns for shareholders.20
Very Negative
Cash Flow
The cash flow statement indicates negative operating and free cash flows, with no substantial growth in free cash flow. The operating cash flow to net income ratio reflects cash outflows, highlighting liquidity issues. Financing activities are primarily sustaining cash needs, illustrating a reliance on external funding.15
Very Negative
| Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 4.36M | 0.00 | 121.94K |
| Gross Profit | -47.37K | 0.00 | -313.00K | 929.65K | -201.00K | 52.21K |
| EBITDA | -10.31M | -14.80M | -14.59M | -11.73M | -10.24M | -7.22M |
| Net Income | -3.62B | -16.58M | -15.29M | -20.07M | -40.27M | -13.56M |
Balance Sheet | ||||||
| Total Assets | 924.18M | 3.66M | 8.27M | 13.76M | 12.89M | 4.68M |
| Cash, Cash Equivalents and Short-Term Investments | 443.91M | 3.11M | 8.02M | 12.59M | 12.26M | 4.30M |
| Total Debt | 5.25B | 5.08M | 2.92M | 2.56M | 9.91M | 4.33M |
| Total Liabilities | 6.81B | 5.82M | 4.52M | 3.90M | 11.65M | 6.60M |
| Stockholders Equity | -5.88B | -2.16M | 3.74M | 9.86M | 1.24M | -1.91M |
Cash Flow | ||||||
| Free Cash Flow | -1.31B | -12.90M | -10.43M | -7.78M | -7.15M | -3.98M |
| Operating Cash Flow | -1.31B | -12.83M | -10.35M | -6.92M | -6.85M | -3.91M |
| Investing Cash Flow | -53.66K | -66.35K | -80.80K | -855.47K | -299.52K | -70.13K |
| Financing Cash Flow | 714.76M | 7.98M | 5.86M | 8.11M | 15.11M | 6.38M |
Know Labs Technical Analysis
Positive
2.45
Price Trends
1.35
Positive
1.61
Positive
4.86
Negative
Market Momentum
0.18
Positive
54.42
Neutral
25.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNW, the sentiment is Positive. The current price of 2.45 is below the 20-day moving average (MA) of 2.67, above the 50-day MA of 1.35, and below the 200-day MA of 4.86, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 54.42 is Neutral, neither overbought nor oversold. The STOCH value of 25.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNW.
Know Labs Risk Analysis
Know Labs disclosed 33 risk factors in its most recent earnings report. Know Labs reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Know Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $64.55M | 41.20 | 12.53% | ― | 22.59% | ― | |
63 Neutral | $34.07B | 6.13 | -11.73% | 1.80% | 5.33% | -18.31% | |
52 Neutral | $1.22B | ― | -56.81% | ― | 28.04% | 64.81% | |
52 Neutral | $1.22B | ― | -56.81% | ― | 28.04% | 64.81% | |
48 Neutral | $79.92M | ― | -131.75% | ― | -20.77% | -2.08% | |
47 Neutral | $564.09M | ― | -1.29% | 0.62% | 11.47% | 99.25% | |
28 Underperform | $18.37M | ― | -2088.74% | ― | ― | 47.57% |
* Technology Sector Average
Performance Comparison
KNW
Know Labs
2.45
-13.35
-84.49%
GNSS
Genasys
1.77
-0.83
-31.92%
MLAB
Mesa Laboratories
103.40
8.74
9.23%
MIND
MIND Technology
8.10
3.80
88.37%
OUST
Ouster
22.73
12.26
117.10%
OUST
Ouster
22.73
12.26
117.10%
Know Labs Corporate Events
Shareholder MeetingsBusiness Operations and Strategy
Know Labs Approves Strategic Amendments for Growth
Positive
Oct 30, 2024
Know Labs, Inc. held a special stockholder meeting where key amendments were approved, including an increase in authorized common stock from 200 million to 300 million shares and an enhancement to the 2021 Equity Incentive Plan by authorizing up to 40 million shares. These changes signify strategic growth plans to attract more investments and enhance shareholder value.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.